Summary

Market Overview
The Global Pancreatic Cancer Diagnostics Market was valued at USD 2.87 billion in 2024 and is projected to reach USD 4.32 billion by 2030, registering a CAGR of 7.05% during the forecast period. The market is gaining momentum due to the growing incidence of pancreatic cancer, increased demand for minimally invasive diagnostic techniques, and rising investments in R&D. Pancreatic cancer remains one of the deadliest forms of cancer due to its silent progression and late-stage detection. As awareness grows around early screening and its impact on survival outcomes, the demand for effective diagnostic tools has increased significantly. Moreover, the aging global population—particularly those aged 60 and above—has contributed to a higher incidence of pancreatic cancer, further driving demand for early detection technologies and diagnostic advancements.
Key Market Drivers
Rising Incidence of Pancreatic Cancer
The rising global incidence of pancreatic cancer serves as a major catalyst for the growth of the pancreatic cancer diagnostics market. According to the American Cancer Society, around 66,440 individuals in the U.S. are expected to be diagnosed with pancreatic cancer in 2024, with an estimated 51,750 fatalities. This high mortality rate emphasizes the urgency for improved diagnostic solutions. Globally, the increasing burden of pancreatic cancer is influenced by aging populations, evolving lifestyles, and environmental risk factors. As the disease is often diagnosed at a late stage due to its aggressive progression, healthcare systems are focusing more on developing advanced diagnostics that enable early and accurate detection.
Key Market Challenges
Late Diagnosis Due to Non-Specific Symptoms
One of the primary obstacles in pancreatic cancer diagnostics is the difficulty in early detection due to vague and non-specific symptoms such as abdominal discomfort, unexplained weight loss, and jaundice. These symptoms often resemble those of less severe conditions, causing significant delays in diagnosis. As a result, patients are frequently diagnosed at advanced stages when treatment options are limited. Although novel tools like the PAC-MANN blood test—showing 85% accuracy when used alongside CA 19-9—present promising results, broader implementation remains hindered by the need for further clinical validation and regulatory approvals.
Key Market Trends
Emphasis on Early Detection and Personalized Medicine
A prominent trend shaping the pancreatic cancer diagnostics market is the increasing emphasis on early detection and the integration of personalized medicine. Advances in diagnostic technologies, including experimental blood tests with up to 97% accuracy for stage 1 and 2 cancers, highlight the potential for improving outcomes through early diagnosis. Simultaneously, personalized approaches based on genetic profiling are gaining traction. Genomic testing enables identification of actionable mutations, allowing clinicians to customize treatment plans. Recent studies indicate that nearly one-third of patients with advanced pancreatic cancer had their treatments modified based on such insights, reinforcing the growing importance of precision diagnostics.
Key Market Players
• Siemens Healthineers AG
• Myriad Genetics, Inc.
• Pfizer, Inc
• Novartis AG
• AstraZeneca plc
• Immunovia AB
• Laboratory Corporation of America Holdings
• Abbott Laboratories
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
Report Scope:
In this report, the Global Pancreatic Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Pancreatic Cancer Diagnostics Market, By Test Type:
o Diagnostic Imaging Tests
o Biopsy
o Blood Tests
o Liver Function Tests
o Others
• Pancreatic Cancer Diagnostics Market, By Cancer Type:
o Exocrine
o Adenocarcinoma
o Squamous Cell Carcinoma
o Colloid Carcinoma
o Others
• Pancreatic Cancer Diagnostics Market, By End User:
o Hospitals & Clinics
o Diagnostic Centers
o Others
• Pancreatic Cancer Diagnostics Market, By Region:
o North America
§ United States
§ Mexico
§ Canada
o Europe
§ France
§ Germany
§ United Kingdom
§ Italy
§ Spain
o Asia-Pacific
§ China
§ India
§ South Korea
§ Japan
§ Australia
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East and Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Diagnostics Market.
Available Customizations:
Global Pancreatic Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Pancreatic Cancer Diagnostics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Test Type (Diagnostic Imaging Tests, Biopsy, Blood Tests, Liver Function Tests, Others)
5.2.1.1. By Diagnostic Imaging Tests (CT scan, MRI, Ultrasound, Others)
5.2.2. By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, Others)
5.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Product Map
5.3.1. By Test Type
5.3.2. By Cancer Type
5.3.3. By End User
5.3.4. By Region
6. North America Pancreatic Cancer Diagnostics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Test Type
6.2.2. By Cancer Type
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Pancreatic Cancer Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type
6.3.1.2.2. By Cancer Type
6.3.1.2.3. By End User
6.3.2. Canada Pancreatic Cancer Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Test Type
6.3.2.2.2. By Cancer Type
6.3.2.2.3. By End User
6.3.3. Mexico Pancreatic Cancer Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test Type
6.3.3.2.2. By Cancer Type
6.3.3.2.3. By End User
7. Europe Pancreatic Cancer Diagnostics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Test Type
7.2.2. By Cancer Type
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Pancreatic Cancer Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Test Type
7.3.1.2.2. By Cancer Type
7.3.1.2.3. By End User
7.3.2. Germany Pancreatic Cancer Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Test Type
7.3.2.2.2. By Cancer Type
7.3.2.2.3. By End User
7.3.3. United Kingdom Pancreatic Cancer Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Test Type
7.3.3.2.2. By Cancer Type
7.3.3.2.3. By End User
7.3.4. Italy Pancreatic Cancer Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Test Type
7.3.4.2.2. By Cancer Type
7.3.4.2.3. By End User
7.3.5. Spain Pancreatic Cancer Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Test Type
7.3.5.2.2. By Cancer Type
7.3.5.2.3. By End User
8. Asia-Pacific Pancreatic Cancer Diagnostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Test Type
8.2.2. By Cancer Type
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Pancreatic Cancer Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type
8.3.1.2.2. By Cancer Type
8.3.1.2.3. By End User
8.3.2. India Pancreatic Cancer Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type
8.3.2.2.2. By Cancer Type
8.3.2.2.3. By End User
8.3.3. Japan Pancreatic Cancer Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type
8.3.3.2.2. By Cancer Type
8.3.3.2.3. By End User
8.3.4. South Korea Pancreatic Cancer Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Test Type
8.3.4.2.2. By Cancer Type
8.3.4.2.3. By End User
8.3.5. Australia Pancreatic Cancer Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Test Type
8.3.5.2.2. By Cancer Type
8.3.5.2.3. By End User
9. South America Pancreatic Cancer Diagnostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Test Type
9.2.2. By Cancer Type
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Pancreatic Cancer Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type
9.3.1.2.2. By Cancer Type
9.3.1.2.3. By End User
9.3.2. Argentina Pancreatic Cancer Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type
9.3.2.2.2. By Cancer Type
9.3.2.2.3. By End User
9.3.3. Colombia Pancreatic Cancer Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type
9.3.3.2.2. By Cancer Type
9.3.3.2.3. By End User
10. Middle East and Africa Pancreatic Cancer Diagnostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Test Type
10.2.2. By Cancer Type
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Pancreatic Cancer Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Test Type
10.3.1.2.2. By Cancer Type
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Pancreatic Cancer Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Test Type
10.3.2.2.2. By Cancer Type
10.3.2.2.3. By End User
10.3.3. UAE Pancreatic Cancer Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Test Type
10.3.3.2.2. By Cancer Type
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Global Pancreatic Cancer Diagnostics Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Siemens Healthineers AG
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Myriad Genetics, Inc.
15.3. Pfizer, Inc
15.4. Novartis AG
15.5. AstraZeneca plc
15.6. Immunovia AB
15.7. Laboratory Corporation of America Holdings
15.8. Abbott Laboratories
15.9. Agilent Technologies, Inc.
15.10. Thermo Fisher Scientific Inc.
16. Strategic Recommendations
17. About Us & Disclaimer